Neuronova
AG Selects Prestwick as their Medicinal Chemistry Partner
November 5, 2004 - News Release
Munich, Germany; Illkirch, France - Neuronova AG, a biopharmaceutical company developing novel drugs against depression, and Prestwick Chemical Inc., an expert in medicinal chemistry, have entered into a collaboration by which Prestwick Chemical will apply its integrated medicinal chemistry platform to optimise a small molecule compound with antidepressant properties identified by Neuronova. more...
Download German version
Neuronova AG Selects Evotec OAI as their Assay Development and Screening Partner
June 14, 2004 - News Release
Munich, Germany; Hamburg, Germany; Oxfordshire, UK - Neuronova AG (private) and Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30), a leading partner for integrated high-value-added drug discovery and development solutions to the pharmaceutical and biotechnology industries, today announced that they have entered into a drug discovery agreement to identify small molecule compounds that interact with a Neuronova target involved in the treatment of depression and anxiety. more...
Download German version
Outstanding research in depression and anxiety is granted "Freedom to Discover Award 2004" by Bristol-Myers Squibb
April 20, 2004 - News Release
Neuronova founder Prof. Florian Holsboer receives award as lead researcher for the Max-Planck-Institute of Psychiatry more...
Download German version
November 5, 2004 - News Release
Munich, Germany; Illkirch, France - Neuronova AG, a biopharmaceutical company developing novel drugs against depression, and Prestwick Chemical Inc., an expert in medicinal chemistry, have entered into a collaboration by which Prestwick Chemical will apply its integrated medicinal chemistry platform to optimise a small molecule compound with antidepressant properties identified by Neuronova. more...
Download German version
Neuronova AG Selects Evotec OAI as their Assay Development and Screening Partner
June 14, 2004 - News Release
Munich, Germany; Hamburg, Germany; Oxfordshire, UK - Neuronova AG (private) and Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30), a leading partner for integrated high-value-added drug discovery and development solutions to the pharmaceutical and biotechnology industries, today announced that they have entered into a drug discovery agreement to identify small molecule compounds that interact with a Neuronova target involved in the treatment of depression and anxiety. more...
Download German version
Outstanding research in depression and anxiety is granted "Freedom to Discover Award 2004" by Bristol-Myers Squibb
April 20, 2004 - News Release
Neuronova founder Prof. Florian Holsboer receives award as lead researcher for the Max-Planck-Institute of Psychiatry more...
Download German version
